Fibromyalgia Treatment Market
Fibromyalgia Treatment Market Study by Antidepressants, Anticonvulsants, and Muscle Relaxants Sold through Hospital Pharmacies, Drug Stores, Retail Pharmacies, and Online Pharmacies from 2024 to 2034
Analysis of Fibromyalgia Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Fibromyalgia Treatment Market Outlook (2024 to 2034)
The global fibromyalgia treatment market size is projected to grow from US$ 1,445.8 million in 2024 to US$ 2,830.1 million by 2034. Over the assessment period, demand for fibromyalgia treatment is projected to increase at 6.9% CAGR.
Demand remains exceptionally high for antidepressants and anticonvulsants in the market owing to their effectiveness in relieving chronic pain associated with fibromyalgia. The target segments are poised to record CAGRs of 7.9% and 6.4%, respectively, through 2034.
Currently, there is no proper cure for fibromyalgia. However, patients use different medications, including antidepressants, analgesics, and anticonvulsants, to ease symptoms and improve quality of life. This is expected to boost the growth of the global fibromyalgia treatment market through 2034.
Fibromyalgia treatment drugs help to relieve the musculoskeletal pain associated with fibromyalgia. They can also improve sleep and emotional health. As a result, their demand is anticipated to rise significantly amid growing cases of fibromyalgia.
The market is also witnessing a transition toward targeted therapies as well as non-pharmacological treatments like physical therapy and cognitive behavior therapy. This will likely foster revenue growth during the assessment period.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 1,445.8 million |
| Projected Market Value (2034F) | US$ 2,830.1 million |
| Global Market Growth Rate (2024 to 2034) | 6.9% CAGR |
| Anticonvulsants Segment Market Share (2034) | 52.6% |
| Online Pharmacies Segment Growth Rate (2024 to 2034) | 8.6% |
| North America Market Share (2034) | 39.9% |
| East Asia Market Share (2034) | 21.2% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Fibromyalgia Treatment Market Analysis
Which Factors Are Fueling Fibromyalgia Treatment Demand?
“Increasing Incidence of Fibromyalgia Globally”
Over the years, there has been a sharp rise in cases of fibromyalgia, a somatization disorder characterized by symptoms like musculoskeletal pain and pain. For instance, as per the National Health Services, around 1 in 20 people globally suffer from fibromyalgia.
Patients who have fibromyalgia often opt for medications like antidepressants and anticonvulsants to relieve pain and other symptoms. Hence, the growing prevalence of fibromyalgia is expected to fuel demand for fibromyalgia therapy during the assessment period.
“Rise in Diagnostic Screen of Fibromyalgia”
Rising awareness and understanding of fibromyalgia among the general public and healthcare professionals is leading to higher diagnostic rates. This, in turn, is expected to generate high demand for fibromyalgia treatments, including medications, cognitive behavior therapy, and acupuncture, among others.
Fibromyalgia medications help to reduce pain, fatigue, and other symptoms of fibromyalgia. Similarly, talking therapies can help to address symptoms like fibro fog. Hence, increasing diagnostic rates of fibromyalgia is predicted to boost the fibromyalgia treatment market growth.
What are the Key Fibromyalgia Treatment Market Trends?
“Introduction of Novel Fibromyalgia Medications and Technologies”
Although there is no permanent cure for fibromyalgia, several drugs help to reduce its symptoms and improve the patient’s quality of life. This is prompting top pharmaceutical companies and research institutes to explore novel fibromyalgia therapies or medications.
New research is being undertaken to study the underlying mechanism of fibromyalgia, leading to the development of new experimental drugs as well as combination therapies. The introduction of new medications or therapies for the management of fibromyalgia is expected to positively impact the global fibromyalgia treatment industry.
Innovations remain at the heart of the fibromyalgia treatment industry. Companies are looking to introduce new fibromyalgia treatment approaches to stay ahead of the competition. For instance, in September 2022, Swing Therapeutics introduced Stanza in the United States.
It is the first digital therapy for fibromyalgia patients. Subsequently, the company received Novo marketing authorization from the FDA from Stanza in May 2023.
Similarly, in November 2022, NeuroMetrix launched Quell Fibromyalgia. It is a wearable neuromodulation technology that is the first and only FDA-authorized medical device to help reduce fibromyalgia symptoms.
The adoption of digital health technologies like wearable devices and mobile apps is expanding the management of fibromyalgia. This is projected to further boost sales growth during the assessment period.
Which Factors Are Limiting Market Expansion?
“Limited Availability of Approved Medications and Side Effects of Fibromyalgia Drugs”
Despite a strong growth prediction, certain factors can limit the expansion of the global fibromyalgia treatment industry. One such factor is the limited availability of approved medications for fibromyalgia treatment.
A limited number of medications are approved by regulatory bodies like the Food and Drug Administration (FDA). As a result, people suffering from fibromyalgia often require off-label treatment, thereby limiting market expansion.
Another factor restraining the growth of the fibromyalgia treatment industry is the side effects of several fibromyalgia drugs. Subsequently, the growing popularity of alternative treatment approaches can negatively impact the market.
Medications like antidepressants (SSRIs) often result in symptoms like tremors, sexual problems, increased heart rate, and others. As a result, several patients refrain from using them.
Country-wise Insights
North America is anticipated to remain at the top of the ladder in the fibromyalgia treatment market, while East Asia is expected to offer lucrative growth opportunities to manufacturers. This is due to the increasing patient pool and the strong presence of pharmaceutical giants.
The East Asia fibromyalgia treatment market is projected to expand with a robust CAGR of 10.3% during the forecast period. It will likely hold a global market share of about 21.2% in 2034, with China and Japan at the forefront.
The North America fibromyalgia treatment industry is projected to register a CAGR of 5.4% over the assessment period. It is set to hold a global market share of 39.9% by 2034, with the United States becoming the hotbed for key players.
What is Propelling Fibromyalgia Treatment Demand in the United States?
“Rising Prevalence of Fibromyalgia Driving Demand in the United States”
The United States fibromyalgia treatment market value is expected to total US$ 939 million in 2034. Over the forecast period, demand for fibromyalgia treatment in the United States is projected to grow at 5.2% CAGR.
Several factors are expected to drive the growth of the fibromyalgia treatment industry in the United States. These include a growing incidence of fibromyalgia, rising preference for personalized treatment, availability of generics, and high level of health awareness among people.
There has been a spike in cases of fibromyalgia in the United States during the last few years. As per the National Fibromyalgia Association (NFA), fibromyalgia affects an estimated 10 million people in the United States. This, in turn, is driving demand for fibromyalgia treatment, and the trend will likely continue through 2034.
The United States is also home to several leading pharmaceutical giants. These companies are striving to develop novel medications targeting specific pain pathways and neurotransmitter regulation. This is expected to improve the United States fibromyalgia treatment market share.
Another key factor anticipated to boost the United States market is the development of new fibromyalgia therapies. Subsequently, increasing the number of fibromyalgia clinics will benefit the target industry.
What is the China Fibromyalgia Treatment Market Forecast?
“Growing Awareness of Fibromyalgia Boosting Market Growth in China”
China’s fibromyalgia treatment market is poised to expand from US$ 106 million in 2024 to US$ 313 million by 2034. Overall sales of fibromyalgia treatment medication in China will likely soar at 11.4% CAGR during the forecast period.
The diagnosis rate of fibromyalgia is rising significantly across China due to growing awareness and increasing government initiatives. This leads to a large pool of patients seeking fibromyalgia treatments, thereby fostering market growth.
The rising geriatric population is another key factor expected to fuel sales of fibromyalgia treatment drugs in China. Similarly, increasing the incidence of rheumatic diseases and traumatic stress disorder will likely benefit the target market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
The below section provides a key into leading segments, their growth projections, and respective shares in the fibromyalgia treatment industry. Based on drug class, the anticonvulsants segment is expected to lead the market, holding a value share of 52.6% in 2034. By distribution channel, the hospital pharmacies segment is estimated to account for a prominent market share of 45.7% in 2024.
Which is the Most Effective Drug Class for Fibromyalgia Treatment?
“Anticonvulsants Remain Widely Accepted Drug Class for Fibromyalgia Treatment”
As per the latest analysis, anticonvulsants are expected to remain highly sought-after drugs for the treatment of fibromyalgia. This is due to their effectiveness in relieving fibromyalgia pain.
Demand for anticonvulsants in fibromyalgia management is poised to grow at 6.4% CAGR during the assessment period. It will likely total US$ 1,488.5 million, contributing a revenue share of 52.6% by 2034.
Anticonvulsants, also known as antiseizure medications or antiepileptic drugs, are gaining wider popularity for fibromyalgia treatment. These medications are used to treat different symptoms of fibromyalgia, including pain and sleep difficulties.
Patients who have fibromyalgia are opting for anticonvulsants like pregabalin and gabapentin to reduce pain. Thes medications are gaining huge traction in chronic pain treatment. Thus, increasing consumption of anticonvulsants for treating fibromyalgia symptoms will likely boost the target segment through 2034.
Which Distribution Channel will Contribute Most to the Market?
“Hospital Pharmacies Witnessing High Sales of Fibromyalgia Treatment Drugs”
Based on the distribution channel, the hospital pharmacies segment is expected to lead the global market, holding a share of 45.7% in 2024. Over the forecast period, the target segment is projected to grow at a CAGR of 5.9%.
Multiple factors are driving the growth of the hospital pharmacies segment. These include ease of accessibility to drugs and generics and a high hospital patient pool. Similarly, hospital pharmacies dominate this industry because of their well-established infrastructure and proficiency in fibromyalgia treatment drugs.
Patients suffering from fibromyalgia often have comorbidities like chronic pain, anxiety, and fatigue. As a result, they visit hospitals regularly and find it convenient to pick up their fibromyalgia medication from hospital pharmacies.
Competitive Landscape
Key players in the fibromyalgia treatment market include FSD Pharma, AbbVie, Inc., Pfizer, Inc., Sanofi, Bayer AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Aptinyx Inc., Johnson & Johnson Services, Inc., Virios Therapeutics, Inc., TONIX Pharmaceutical Holdings Corp, and Eli Lilly and Company.
Key manufacturers of fibromyalgia treatment drugs are investing rigorously in research and development to explore new & effective fibromyalgia drugs. They are also looking to get fast-track drug approval from regulatory bodies like the United States Food and Drug Administration (FDA).
Several companies also adopt strategies like partnerships, alliances, distribution agreements, facility expansions, collaborations, and acquisitions. These strategies are expected to enable them to expand their footprint and significantly stay ahead of the competition.
Recent Developments in the Fibromyalgia Treatment Market-
- In April 2021, FSD Pharma Inc. acquired the Canada-based specialty psychedelic pharmaceutical business Lucid Psycheceuticals Inc.
- In October 2023, NeuroMetrix, Inc. collaborated with the National Fibromyalgia Association to improve the quality of life of patients with fibromyalgia.
- In December 2023, AbbVie Inc. collaborated with BigHat Biosciences to discover and develop next-generation therapeutic antibodies in neuroscience and oncology.
- In January 2020, Axsome Therapeutics entered into an agreement with Pfizer Inc. for Prizer’s Reboxetine clinical and nonclinical data. Under this agreement, Axsome also received the exclusive right to develop and commercialize esreboxetine, a novel late-stage product, in the United States for the treatment of fibromyalgia.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Fibromyalgia Treatment Market Segmentation
-
By Drug Class:
- Antidepressants
- Anticonvulsants
- Muscle Relaxants
- Analgesics
-
By Distribution Channel:
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Online Pharmacies
-
By Region:
- North America
- Europe
- Latin America
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ million) & Volume (Units Pack) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ million) & Volume (Units Pack) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) & Volume (Units Pack) Analysis By Drug Class, 2019 to 2023 5.3. Current and Future Market Size Value (US$ million) & Volume (Units Pack) Analysis and Forecast By Drug Class, 2024 to 2034 5.3.1. Antidepressants 5.3.2. Anticonvulsants 5.3.3. Muscle Relaxants 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) & Volume (Units Pack) Analysis By Distribution Channel, 2019 to 2023 6.3. Current and Future Market Size Value (US$ million) & Volume (Units Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034 6.3.1. Hospital Pharmacies 6.3.2. Drug Stores 6.3.3. Retail Pharmacies 6.3.4. Online Pharmacies 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ million) & Volume (Units Pack) Analysis By Region, 2019 to 2023 7.3. Current Market Size Value (US$ million) & Volume (Units Pack) Analysis and Forecast By Region, 2024 to 2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 8.1. Historical Market Size Value (US$ million) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 8.2. Market Size Value (US$ million) & Volume (Units Pack) Forecast By Market Taxonomy, 2024 to 2034 8.2.1. By Country 8.2.1.1. United States 8.2.1.2. Canada 8.2.2. By Drug Class 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Drug Class 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ million) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ million) & Volume (Units Pack) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Drug Class 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ million) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ million) & Volume (Units Pack) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Drug Class 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ million) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ million) & Volume (Units Pack) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Drug Class 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ million) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ million) & Volume (Units Pack) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Drug Class 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ million) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ million) & Volume (Units Pack) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ million) & Volume (Units Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ million) & Volume (Units Pack) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of Middle East & Africa 14.2.2. By Drug Class 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. United States 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2024 15.1.2.1. By Drug Class 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2024 15.2.2.1. By Drug Class 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2024 15.3.2.1. By Drug Class 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2024 15.4.2.1. By Drug Class 15.4.2.2. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2024 15.5.2.1. By Drug Class 15.5.2.2. By Distribution Channel 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2024 15.6.2.1. By Drug Class 15.6.2.2. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2024 15.7.2.1. By Drug Class 15.7.2.2. By Distribution Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2024 15.8.2.1. By Drug Class 15.8.2.2. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2024 15.9.2.1. By Drug Class 15.9.2.2. By Distribution Channel 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2024 15.10.2.1. By Drug Class 15.10.2.2. By Distribution Channel 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2024 15.11.2.1. By Drug Class 15.11.2.2. By Distribution Channel 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2024 15.12.2.1. By Drug Class 15.12.2.2. By Distribution Channel 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2024 15.13.2.1. By Drug Class 15.13.2.2. By Distribution Channel 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2024 15.14.2.1. By Drug Class 15.14.2.2. By Distribution Channel 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2024 15.15.2.1. By Drug Class 15.15.2.2. By Distribution Channel 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2024 15.16.2.1. By Drug Class 15.16.2.2. By Distribution Channel 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2024 15.17.2.1. By Drug Class 15.17.2.2. By Distribution Channel 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2024 15.18.2.1. By Drug Class 15.18.2.2. By Distribution Channel 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2024 15.19.2.1. By Drug Class 15.19.2.2. By Distribution Channel 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2024 15.20.2.1. By Drug Class 15.20.2.2. By Distribution Channel 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2024 15.21.2.1. By Drug Class 15.21.2.2. By Distribution Channel 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2024 15.22.2.1. By Drug Class 15.22.2.2. By Distribution Channel 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2024 15.23.2.1. By Drug Class 15.23.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Class 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. AbbVie Inc 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Sun Pharmaceutical Industries Limited 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Teva Pharmaceutical Industries Ltd 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Viatris Inc 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Amillioneal Pharmaceuticals LLC 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Eli Lilly and Company 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Abbott Laboratories 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Novartis AG 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Lupin Limited 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Zydus Lifesciences Limited 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ million) Forecast by Region, 2019 to 2034
Table 2: Global Market Volume (Units Pack) Forecast by Region, 2019 to 2034
Table 3: Global Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 4: Global Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 5: Global Market Value (US$ million) Forecast by Distribution Channel, 2019 to 2034
Table 6: Global Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 7: North America Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 8: North America Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 9: North America Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 10: North America Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 11: North America Market Value (US$ million) Forecast by Distribution Channel, 2019 to 2034
Table 12: North America Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 13: Latin America Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 14: Latin America Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 15: Latin America Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 16: Latin America Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 17: Latin America Market Value (US$ million) Forecast by Distribution Channel, 2019 to 2034
Table 18: Latin America Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 19: Western Europe Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 20: Western Europe Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 21: Western Europe Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 22: Western Europe Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 23: Western Europe Market Value (US$ million) Forecast by Distribution Channel, 2019 to 2034
Table 24: Western Europe Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 25: Eastern Europe Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 26: Eastern Europe Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 27: Eastern Europe Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 28: Eastern Europe Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 29: Eastern Europe Market Value (US$ million) Forecast by Distribution Channel, 2019 to 2034
Table 30: Eastern Europe Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 31: South Asia and Pacific Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 32: South Asia and Pacific Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 33: South Asia and Pacific Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 34: South Asia and Pacific Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 35: South Asia and Pacific Market Value (US$ million) Forecast by Distribution Channel, 2019 to 2034
Table 36: South Asia and Pacific Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 37: East Asia Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 38: East Asia Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 39: East Asia Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 40: East Asia Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 41: East Asia Market Value (US$ million) Forecast by Distribution Channel, 2019 to 2034
Table 42: East Asia Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
Table 43: Middle East and Africa Market Value (US$ million) Forecast by Country, 2019 to 2034
Table 44: Middle East and Africa Market Volume (Units Pack) Forecast by Country, 2019 to 2034
Table 45: Middle East and Africa Market Value (US$ million) Forecast by Drug Class, 2019 to 2034
Table 46: Middle East and Africa Market Volume (Units Pack) Forecast by Drug Class, 2019 to 2034
Table 47: Middle East and Africa Market Value (US$ million) Forecast by Distribution Channel, 2019 to 2034
Table 48: Middle East and Africa Market Volume (Units Pack) Forecast by Distribution Channel, 2019 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 2: Global Market Value (US$ million) by Distribution Channel, 2024 to 2034
Figure 3: Global Market Value (US$ million) by Region, 2024 to 2034
Figure 4: Global Market Value (US$ million) Analysis by Region, 2019 to 2034
Figure 5: Global Market Volume (Units Pack) Analysis by Region, 2019 to 2034
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 8: Global Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 9: Global Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 12: Global Market Value (US$ million) Analysis by Distribution Channel, 2019 to 2034
Figure 13: Global Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 14: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 15: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 16: Global Market Attractiveness by Drug Class, 2024 to 2034
Figure 17: Global Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 18: Global Market Attractiveness by Region, 2024 to 2034
Figure 19: North America Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 20: North America Market Value (US$ million) by Distribution Channel, 2024 to 2034
Figure 21: North America Market Value (US$ million) by Country, 2024 to 2034
Figure 22: North America Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 23: North America Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 24: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 25: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 26: North America Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 27: North America Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 28: North America Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 29: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 30: North America Market Value (US$ million) Analysis by Distribution Channel, 2019 to 2034
Figure 31: North America Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 32: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 33: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 34: North America Market Attractiveness by Drug Class, 2024 to 2034
Figure 35: North America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 36: North America Market Attractiveness by Country, 2024 to 2034
Figure 37: Latin America Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 38: Latin America Market Value (US$ million) by Distribution Channel, 2024 to 2034
Figure 39: Latin America Market Value (US$ million) by Country, 2024 to 2034
Figure 40: Latin America Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 41: Latin America Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 42: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 43: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 44: Latin America Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 45: Latin America Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 48: Latin America Market Value (US$ million) Analysis by Distribution Channel, 2019 to 2034
Figure 49: Latin America Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 50: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 51: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 52: Latin America Market Attractiveness by Drug Class, 2024 to 2034
Figure 53: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 54: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 55: Western Europe Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 56: Western Europe Market Value (US$ million) by Distribution Channel, 2024 to 2034
Figure 57: Western Europe Market Value (US$ million) by Country, 2024 to 2034
Figure 58: Western Europe Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 59: Western Europe Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 60: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 61: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 62: Western Europe Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 63: Western Europe Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 64: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 65: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 66: Western Europe Market Value (US$ million) Analysis by Distribution Channel, 2019 to 2034
Figure 67: Western Europe Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 68: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 69: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 70: Western Europe Market Attractiveness by Drug Class, 2024 to 2034
Figure 71: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 72: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 73: Eastern Europe Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 74: Eastern Europe Market Value (US$ million) by Distribution Channel, 2024 to 2034
Figure 75: Eastern Europe Market Value (US$ million) by Country, 2024 to 2034
Figure 76: Eastern Europe Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 77: Eastern Europe Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 78: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 79: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 80: Eastern Europe Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 81: Eastern Europe Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 82: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 83: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 84: Eastern Europe Market Value (US$ million) Analysis by Distribution Channel, 2019 to 2034
Figure 85: Eastern Europe Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 88: Eastern Europe Market Attractiveness by Drug Class, 2024 to 2034
Figure 89: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 90: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 91: South Asia and Pacific Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 92: South Asia and Pacific Market Value (US$ million) by Distribution Channel, 2024 to 2034
Figure 93: South Asia and Pacific Market Value (US$ million) by Country, 2024 to 2034
Figure 94: South Asia and Pacific Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 95: South Asia and Pacific Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 96: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 97: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 98: South Asia and Pacific Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 99: South Asia and Pacific Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 100: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 101: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 102: South Asia and Pacific Market Value (US$ million) Analysis by Distribution Channel, 2019 to 2034
Figure 103: South Asia and Pacific Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 104: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 105: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 106: South Asia and Pacific Market Attractiveness by Drug Class, 2024 to 2034
Figure 107: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 108: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 109: East Asia Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 110: East Asia Market Value (US$ million) by Distribution Channel, 2024 to 2034
Figure 111: East Asia Market Value (US$ million) by Country, 2024 to 2034
Figure 112: East Asia Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 113: East Asia Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 114: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 115: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 116: East Asia Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 117: East Asia Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 118: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 119: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 120: East Asia Market Value (US$ million) Analysis by Distribution Channel, 2019 to 2034
Figure 121: East Asia Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 122: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 123: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 124: East Asia Market Attractiveness by Drug Class, 2024 to 2034
Figure 125: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 126: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 127: Middle East and Africa Market Value (US$ million) by Drug Class, 2024 to 2034
Figure 128: Middle East and Africa Market Value (US$ million) by Distribution Channel, 2024 to 2034
Figure 129: Middle East and Africa Market Value (US$ million) by Country, 2024 to 2034
Figure 130: Middle East and Africa Market Value (US$ million) Analysis by Country, 2019 to 2034
Figure 131: Middle East and Africa Market Volume (Units Pack) Analysis by Country, 2019 to 2034
Figure 132: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 133: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 134: Middle East and Africa Market Value (US$ million) Analysis by Drug Class, 2019 to 2034
Figure 135: Middle East and Africa Market Volume (Units Pack) Analysis by Drug Class, 2019 to 2034
Figure 136: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2024 to 2034
Figure 137: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2024 to 2034
Figure 138: Middle East and Africa Market Value (US$ million) Analysis by Distribution Channel, 2019 to 2034
Figure 139: Middle East and Africa Market Volume (Units Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 140: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 141: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 142: Middle East and Africa Market Attractiveness by Drug Class, 2024 to 2034
Figure 143: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 144: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the fibromyalgia treatment market?
The global market value is set to total US$ 1,445.8 million in 2024.
At what rate will fibromyalgia treatment demand rise through 2034?
Global demand is projected to grow at 6.9% CAGR through 2034.
What is the projected market size in 2034?
The fibromyalgia treatment market is projected to reach US$ 2,830.1 million in 2034.
What is the demand outlook for the North America market?
Demand in North America is set to rise at 5.4% CAGR through 2034.
What is the sales forecast for China market?
Sales of fibromyalgia treatment drugs in China are expected to soar at 11.4% CAGR.
Fibromyalgia Treatment Market